Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

NCT04301011 is registered in ClinicalTrials.gov with Turnstone Biologics, Corp. as lead sponsor.

NCT NCT04301011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04301011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
Lead sponsor
Turnstone Biologics, Corp.
Phase
Phase 1
Overall status
Terminated
Start date
June 2, 2020
Completion date
January 23, 2023
Enrollment
27 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cutaneous squamous cell carcinoma, hpv positive oropharyngeal squamous cell carcinoma, melanoma (skin), mesothelioma, microsatellite stable colorectal cancer, oropharynx cancer, renal cell carcinoma, solid tumor